-
ABOUT USHebei Guangxiang Pharmaceutical Co., Ltd. is specializing in the production of bulk pharmaceuticals, fine pharmaceuticals, intermediate compounds and biopharmaceutical preparations.
-
News CenterAt the forefront of corporate development, we champion the positive energy of the Four Pharmaceutical Companies: fulfilling our duties conscientiously, stepping up to the plate and taking proactive action, embracing new missions, and conducting effective new publicity. In doing so, we aim to enhance the overall competence of our employees, stimulate their enthusiasm, initiative, and creativity, and provide robust ideological guidance and powerful spiritual strength to drive the enterprise forward.
-
INNOVATIONDevelops fine, series, high-end bulk pharmaceutical intermediates and innovative bulk pharmaceutical intermediates with high added value to build variety competition advantages.
-
-
RECRUITGuangxiang has jointly established engineering laboratories, technology research centers and other high-level innovation platforms with CAS, Zhejiang University, Tianjin University and other universities.
-
CONTACTWith stable production, high-quality and reliable service, the company's products have been sold to more than 80 countries such as the United States, the United Kingdom, Germany and the Netherlands
Guangxiang Pharmaceutical of Shijiazhuang Sihua Pharmaceutical Group Receives Approval for Drotaverine Hydrochloride
Category:
TIME：2025-08-07
On August 6, the active pharmaceutical ingredient of drotaverine hydrochloride developed by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, was approved by the National Medical Products Administration and registered as an API for use in marketed dosage forms.
According to available information, drotaverine hydrochloride is indicated for the treatment of smooth-muscle spasms associated with biliary tract disorders (such as gallstones and bile duct stones, as well as cholecystitis and cholangitis) and urological disorders (such as renal and ureteral stones, and pyelonephritis and cystitis). It is also used as an adjunctive therapy for smooth-muscle spasms caused by gastrointestinal disorders (including gastric and duodenal ulcers, gastritis, enteritis, colitis, and other inflammatory conditions) and for the relief of dysmenorrhea.
In recent years, the Group has demonstrated strong momentum in its integrated “API–formulation” development model, effectively facilitating the continuous translation of corporate innovation into commercial success. Since the beginning of this year, a total of 12 new API products have been approved, with Guangxiang Pharmaceutical accounting for 8 of these approvals. To date, the Group holds 79 bulk and specialty API varieties, further strengthening its supply-chain resilience and capability.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
E-mail: hbgxzy@hebgxzy.com
Address: The west of Jingliu Road, lingang economic nad technological development zone, cangzhou city, Hebei province
Website
Official WeChat
e-Home
